Chapter 1. CLINICAL TRIALS SERVICES MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. CLINICAL TRIALS SERVICES MARKET – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. CLINICAL TRIALS SERVICES MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. CLINICAL TRIALS SERVICES MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. CLINICAL TRIALS SERVICES MARKET - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. CLINICAL TRIALS SERVICES MARKET – By Type

6.1 Pilot studies and feasibility studies

6.1.1. Prevention trials

6.1.2. Screening trials

6.1.3. Treatment trials

6.2. Multi-arm multi-stage

6.2.1. Cohort studies

6.2.2. Case-control studies

6.2.3. Cross-sectional studies

Chapter 7. CLINICAL TRIALS SERVICES MARKET– By Phase

7.1 Phase I

7.2. Phase II

7.3. Phase III

7.4. Phase IV

Chapter 8. CLINICAL TRIALS SERVICES MARKET – By Region

8.1. North America                           

8.2. Europe

8.3.The Asia Pacific

8.4.Latin America

8.5. Middle-East and Africa

Chapter 9. CLINICAL TRIALS SERVICES MARKET  – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

9.1. Clinipace,

9.2. Laboratory Corporation of America,

9.3. ICON PLC,

9.4. Eli Lilly and Company,

9.5. Novo Nordisk AS

9.6. Syneos Health

9.7. Pfizer

9.8. PAREXEL International Corporation

9.9. Bio-Optronics, Inc.

9.10. Forte Research Systems